ENSEMBLE

E854996

ENSEMBLE is the large, global Phase 3 clinical trial that evaluated the safety and efficacy of Johnson & Johnson’s single-dose Ad26.COV2.S COVID-19 vaccine.

All labels observed (1)

Label Occurrences
ENSEMBLE canonical 1

How this entity was disambiguated

Statements (40)

Predicate Object
instanceOf COVID-19 vaccine trial ⓘ
Phase 3 clinical trial ⓘ
clinical trial ⓘ
controlType placebo ⓘ
diseaseTarget COVID-19 ⓘ
linked to: COVID-19 pandemic
doseRegimen single dose ⓘ
efficacyAssessment monitored incidence of laboratory-confirmed COVID-19 ⓘ
endpoint assessment of safety profile ⓘ
prevention of moderate to severe COVID-19 ⓘ
prevention of severe COVID-19 ⓘ
evaluatedProduct Ad26.COV2.S ⓘ
Johnson & Johnson single-dose COVID-19 vaccine ⓘ
geographicScope multiple countries ⓘ
interventionType vaccine ⓘ
pathogenTarget SARS-CoV-2 ⓘ
population adult participants ⓘ
primaryObjective evaluate efficacy of Ad26.COV2.S against COVID-19 ⓘ
regimenCharacteristic single-shot COVID-19 vaccine ⓘ
relatedVaccineName Ad26.COV2.S COVID-19 vaccine ⓘ
Janssen COVID-19 Vaccine ⓘ
safetyAssessment monitored adverse events after vaccination ⓘ
scope global ⓘ
large ⓘ
secondaryObjective evaluate immunogenicity of Ad26.COV2.S ⓘ
evaluate safety of Ad26.COV2.S ⓘ
sponsor Janssen Pharmaceutical Companies of Johnson & Johnson ⓘ
Johnson & Johnson ⓘ
sponsorCountry United States ⓘ
sponsorOrganizationType pharmaceutical company ⓘ
sponsorType industry ⓘ
studyDesign double-blind ⓘ
placebo-controlled ⓘ
randomized ⓘ
therapeuticArea infectious diseases ⓘ
vaccinology ⓘ
trialCategory pivotal efficacy trial ⓘ
trialContext COVID-19 pandemic ⓘ
trialPhase Phase 3 ⓘ
vaccinePlatform adenoviral vector vaccine ⓘ
vaccineVector recombinant, replication-incompetent human adenovirus serotype 26 (Ad26) ⓘ

How these facts were elicited

Referenced by (1)

Full triples — surface form annotated when it differs from this entity's canonical label.

Ad26.COV2.S → trialName → ENSEMBLE ⓘ